Based on the clinical evidence and the patient profiles where the compound appears most applicable, the following characteristics tend to describe good candidates for AOD 9604 evaluation when it is medically supervised: Patients with stubborn localized fat deposits that have not responded to diet and exercise, particularly visceral and lower abdominal fat Patients who cannot tolerate GLP-1 medications due to nausea, gastrointestinal side effects, or contraindications Active patients with reasonable baseline metabolic health who want a targeted lipolytic tool to complement their training and nutrition program Patients already on a peptide protocol who want to add a fat-targeting element to a GHK-Cu, NAD+, or sermorelin stack Patients who are not candidates for stimulant-based fat loss medications due to cardiovascular sensitivity, anxiety, or blood pressure concerns AOD 9604 is not appropriate as a standalone weight loss strategy for patients with significant obesity, insulin resistance, or metabolic syndrome
The compound has been studied in models of traumatic brain injury, peripheral nerve damage, neurotoxicity, and mood disorders producing results that have surprised many researchers given the peptides gastrointestinal origins
Risks include: Contamination with bacteria or fungi Endotoxin (bacterial cell wall fragments) that remain even after sterilization Severe inflammatory reactions or sepsis D
BPC-157 is not FDA-approved for any human indication
A 2018 rat study showed that it increased GH receptor expression in tendon cells and activated key growth pathways, making tissues more responsive to circulating GH
